Northwire Canada EditionFriday, July 10, 2026
Northwire
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Earnings Material +

Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results

BAT Debt Swap and Medicare Pilot Buy Time as Cash Burn Persists

Executive Summary
  • Charlotte's Web reported Q4 2025 revenue of $13.3M (+4.7% YoY) and full-year 2025 revenue of $49.9M (+0.5% YoY), marking the first annual revenue increase since 2021.
  • The company posted a Q4 net loss of $11.5M and a full-year net loss of $29.7M, with adjusted EBITDA of -$4.4M for Q4 and -$12.9M for FY2025.
  • Cash and cash equivalents fell sharply to $8.0M from $22.6M, leaving the company with a shareholder equity deficit of $(2.0)M.
  • A definitive transaction with BAT DE Investments was announced: conversion of a C$75.3M convertible debenture plus accrued interest, alongside a US$10M private placement equity investment at C$0.94 per share.
  • Post-transaction, BAT will hold approximately 40% of outstanding common shares, eliminating the company's largest debt liability and halting ~US$12M in future interest expenses.
  • Proceeds are earmarked for the CMMI Medicare pilot program launch (effective April 1, 2026) and continued funding of the DeFloria AJA001 Phase 2 clinical trial for autism spectrum disorder.
  • The transaction requires TSX and shareholder approval, targeted for the AGM/Special Meeting around May 28, 2026.
Material Impact
  • The BAT transaction is structurally transformative, removing an existential debt overhang and injecting immediate liquidity into a critically thin balance sheet.
  • The 40% equity stake granted to BAT represents severe dilution for existing shareholders, fundamentally altering the capital structure and shifting control dynamics.
  • Financial results confirm management's cost-cutting narrative (SG&A down YoY, manufacturing internalization progressing), but top-line growth remains anemic and cash burn persists.
  • The CMMI Medicare pilot provides a tangible, federally backed commercial catalyst, but initial revenue contribution is unproven and dependent on complex reimbursement mechanics.
  • Overall, the news resolves near-term solvency risk and validates the strategic pivot toward medical and pharmaceutical channels, but execution risk and dilution cap immediate upside.
CWEB · Price
Company Overview
  • Charlotte's Web is a U.S.-based botanical wellness company specializing in hemp-derived CBD, low-dose Delta-9 THC, and functional mushroom products.
  • Flagship Project: The Brightside line of precision-formulated, fast-acting hemp-derived THC gummies utilizing proprietary TiME INFUSION technology. This line targets the rapidly growing hemp-THC wellness segment and is now ~75% produced in-house to improve margins.
  • Secondary Initiatives: Expansion into functional mushroom sleep aids, omnichannel digital distribution (Amazon, TikTok Shop, Faire), and the DeFloria joint venture developing AJA001 for autism-related irritability.
Read the original news release →

More from CHARLOTTE'S WEB HOLDINGS, INC.